180 documents

Read All
20:54 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

ChemoCentryx, Vifor Fresenius to seek full approval of avacopan next year

ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma Ltd. voluntarily withdrew a conditional marketing authorization (CMA) application in the EU for avacopan (CCX168) to treat antineutrophil cytoplasmic antibody associated vasculitis, since Phase...
Read More
23:44 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
Read More
18:49 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
Read More
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
Read More
16:40 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data at...
Read More
22:32 , Jan 23, 2018 |  BC Extra  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data on...
Read More
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
Read More
00:44 , Jan 5, 2018 |  BC Extra  |  Company News

ChemoCentryx gains after EMA validates avacopan MAA

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $2.44 (39%) to $8.63 Thursday after it said EMA validated an MAA for avacopan (CCX168), triggering a $50 million milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. ChemoCentryx also...
Read More
20:58 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Mouse studies suggest inhibiting CCR2 in combination with radiotherapy could help treat colon and lung cancers. In mouse models of colon and lung cancers, systemic knockout of CCR2 plus radiation...
Read More
19:22 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
Read More